Clinical Development - On October 31, 2023, preliminary topline results for VAL-083 indicated it did not perform better than current standards of care in glioblastoma, leading to the termination of its development[75]. - The company received a $2,000 grant from the NIH to fund the majority of expenses related to the REM-001 CMBC 15-patient clinical study, with the grant awarded over a two-year period[77]. - As of May 14, 2024, treatment has been initiated in 2 patients for the REM-001 Study, with expectations to complete enrollment in the third calendar quarter of 2024[79]. - The REM-001 therapy has shown a complete response in approximately 80% of evaluable tumor sites treated in previous studies[78]. - The FDA has granted Fast Track Designation for REM-001 in CMBC, facilitating its clinical development[80]. - The company terminated the development of VAL-083 and assigned its rights to Valent, receiving a 5% royalty on future net sales[81]. Financial Performance - As of March 31, 2024, total assets increased to $7,446,000 from $3,979,000 as of June 30, 2023, representing an increase of 87.5%[87]. - Research and development expenses decreased by 70% to $592,000 for the three months ended March 31, 2024, compared to $2,005,000 for the same period in 2023[94]. - General and administrative expenses increased by 15% to $1,493,000 for the three months ended March 31, 2024, compared to $1,297,000 for the same period in 2023[96]. - The net loss for the three months ended March 31, 2024, was $2,011,000, a decrease of 38.4% from a net loss of $3,264,000 for the same period in 2023[93]. - For the nine months ended March 31, 2024, research and development expenses decreased to $2,562,000 from $7,235,000, a reduction of 65%[97]. - The company received $194,000 in grant proceeds during the three months ended March 31, 2024, compared to nil in the same period in 2023[95]. - The total stockholders' equity increased to $5,922,000 as of March 31, 2024, from $731,000 as of June 30, 2023[87]. - The company reported net losses of $5,996 for the nine months ended March 31, 2024, compared to $11,314 for the same period in 2023[102]. - Net cash used in operating activities was $5,734 for the nine months ended March 31, 2024, a 45% improvement from $10,357 in the same period in 2023[105]. - Net cash received from financing activities increased significantly to $10,570 for the nine months ended March 31, 2024, compared to $1,854 in the same period in 2023, marking a 470% increase[104]. Strategic Initiatives - A merger agreement was entered into on April 3, 2024, with TuHURA Biosciences, where existing stockholders are expected to own approximately 2.85% of the post-merger company on a fully diluted basis[76]. - The transaction with TuHURA is expected to close in the third calendar quarter of 2024, pending stockholder and regulatory approval[82]. - The company has initiated a process to explore strategic alternatives aimed at maximizing stockholder value as of December 2023[75]. - The company entered into a Merger Agreement with TuHURA, indicating a strategic move to maximize shareholder value[106]. - The company anticipates requiring significant additional funding to maintain clinical trials and operations, indicating substantial doubt about its ability to continue as a going concern[106]. Shareholder Information - The weighted average number of shares for the three months ended March 31, 2024, was 44,562, compared to 1,681 for the same period in 2023[89]. - The Series C Preferred Stock is convertible into common stock at prices ranging from $57.50 to $60.70 per share[86]. - The company raised $10,471 in net proceeds from the sale of shares under its ATM Facility from October 31, 2023, to March 31, 2024[106].

Financial Performance - As of December 31, 2023, Kintara reported cash and cash equivalents of $658,000, down from $1,535,000 on June 30, 2023[87]. - The company incurred a net loss of $1,023,000 for the three months ended December 31, 2023, compared to a net loss of $3,454,000 for the same period in 2022[88]. - Net loss for the six months ended December 31, 2023, was $3,985, compared to a net loss of $8,050 for the same period in 2022, representing an improvement of 50%[99]. - For the six months ended December 31, 2023, the company reported a loss of $3,985 and a negative cash flow from operations of $3,434[106]. - The company has an accumulated deficit of $155,537 and cash and cash equivalents of $658 as of December 31, 2023[106]. Research and Development - Kintara announced the termination of the VAL-083 development program after preliminary results showed it did not perform better than current standards of care for glioblastoma[76]. - Research and development expenses decreased to $111,000 for the three months ended December 31, 2023, from $2,059,000 in the same period of 2022[88]. - Research and development expenses decreased to $1,970 for the six months ended December 31, 2023, from $5,230 for the same period in 2022, a reduction of 62%[99]. - The company plans to initiate a 15-patient open-label study for REM-001 in CMBC patients in the first quarter of 2024[78]. - The company received $2 million in grant funding for the REM-001 program, which is expected to ramp up in the first calendar quarter of 2024[95]. Funding and Grants - Kintara Therapeutics received a $2.0 million grant from the NIH to fund the REM-001 CMBC clinical study over a two-year period[76]. - The company was awarded approximately $2.0 million in grant funding for the REM-001 project on June 28, 2023[106]. - The company received $210 in clinical grant funding during the six months ended December 31, 2023[104]. - The company raised approximately $2,579 in net proceeds from the sale of 8,013 shares of common stock under the ATM Facility from October 31, 2023, to December 31, 2023[106]. - An additional $6,108 in net proceeds was raised from the sale of 28,870 shares of common stock under the ATM Facility from January 1, 2024, to February 12, 2024[106]. Operational Challenges - Kintara received a Notice from Nasdaq regarding non-compliance with the Stockholders' Equity Requirement, with a compliance plan submitted and an extension until March 18, 2024[76]. - The company is exploring strategic alternatives to maximize stockholder value as of December 2023[77]. - The company is exploring various financing alternatives to fund operations and maximize shareholder value[106]. - The company may need to delay, reduce, or eliminate clinical trials or research programs if additional funding is not secured[107]. - Future funding requirements will depend on the progress and costs of clinical studies and other factors[106]. Assets and Equity - Kintara's total assets decreased to $1,885,000 as of December 31, 2023, from $3,979,000 on June 30, 2023[87]. - The company has 39,038 shares of common stock issued and outstanding as of February 12, 2024[85]. - The company has no off-balance sheet arrangements[110]. Expenses - General and administrative expenses were $2,011 for the six months ended December 31, 2023, compared to $2,915 for the same period in 2022, a decrease of 31%[100]. - Non-cash, share-based compensation expense decreased to $301 for the six months ended December 31, 2023, from $680 for the same period in 2022[100]. - Net cash used in operating activities was $3,434 for the six months ended December 31, 2023, compared to $8,530 for the same period in 2022, a reduction of 60%[102]. - Clinical trial deposit usage for settling expenses was $961 during the six months ended December 31, 2023[102].

Funding and Grants - Kintara Therapeutics received a $2.0 million grant from the NIH to fund the REM-001 CMBC clinical study over two years[78]. - The company received a $2 million grant for the REM-001 project, which was announced on June 28, 2023[110]. - The company entered into a Sales Agreement allowing for the sale of up to $2.85 million in common stock, with $968,000 raised in net proceeds from the sale of shares under this agreement after September 30, 2023[110]. - The company is actively pursuing various financing alternatives to fund operations and maintain clinical trials, indicating substantial doubt about its ability to continue as a going concern[111]. Clinical Studies and Development - Preliminary results from the VAL-083 study indicated it did not outperform current glioblastoma treatments, leading to the suspension of its development[84]. - The company plans to start enrolling patients in the REM-001 CMBC clinical study in Q4 2023[80]. - In previous studies, REM-001 Therapy achieved a complete response in approximately 80% of evaluable tumor sites treated[82]. - The REM-001 program was previously paused to conserve cash but has been reinitiated following the NIH grant[78]. - Kintara's focus is on developing therapies for patients with solid tumors resistant to current treatments, particularly in orphan cancer indications[76]. - Kintara has received Fast Track Designation from the FDA for both VAL-083 and REM-001 in their respective indications[88][83]. Financial Performance - As of September 30, 2023, Kintara had cash and cash equivalents of $216,000, down from $1,535,000 on June 30, 2023[95]. - Total assets decreased from $3,979,000 on June 30, 2023, to $1,477,000 on September 30, 2023[95]. - The company's total stockholders' equity showed a deficiency of $2,026,000 as of September 30, 2023, compared to $731,000 on June 30, 2023[95]. - Net loss for the period was $2,962,000 for the three months ended September 30, 2023, compared to a net loss of $4,596,000 for the same period in 2022, indicating a 35% improvement[100]. - Cash flows from operating activities improved to $(1,317,000) for the three months ended September 30, 2023, from $(6,369,000) for the same period in 2022, a 79% reduction in cash outflow[106]. Expenses - Research and development expenses decreased to $1,859,000 for the three months ended September 30, 2023, from $3,171,000 for the same period in 2022, representing a 41% decrease[100]. - General and administrative expenses were $1,103,000 for the three months ended September 30, 2023, compared to $1,475,000 for the same period in 2022, a reduction of 25%[100]. - Non-cash, share-based compensation expense for research and development decreased to $86,000 in Q3 2023 from $140,000 in Q3 2022[101]. - Non-cash, share-based compensation expense for general and administrative costs decreased to $121,000 in Q3 2023 from $378,000 in Q3 2022[103]. Stock Options and Compensation - The company recognizes compensation costs from stock-based awards over the service period based on fair value measurements, with adjustments made for actual forfeitures[114]. - For the three months ended September 30, 2023, the company issued stock options to its officers, with fair value estimated using the Black-Scholes model[114]. Clinical Trial Expenses - The company estimates expenses related to clinical trials based on contracts with vendors and adjusts accruals as necessary, with no material adjustments reported for the three months ended September 30, 2023[115]. - The company does not have any off-balance sheet arrangements[116].

Funding and Grants - The company was awarded a $2.0 million grant from the National Institutes of Health (NIH) effective July 1, 2023, to fund the majority of expenses related to the REM-001 CMBC 15-patient clinical study[7]. - The company received a $2.0 million grant from the National Institutes of Health (NIH) effective July 1, 2023, to fund the REM-001 CMBC 15-patient clinical study[7]. Clinical Studies and Results - Topline results from the GBM AGILE Study for VAL-083 are expected prior to the end of calendar year 2023[8]. - The GBM AGILE Study has screened over 1,300 patients, with enrollment rates 3 to 4 times greater than traditional GBM studies[23]. - VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly-diagnosed methylated MGMT, newly-diagnosed unmethylated MGMT, and recurrent[11]. - The company has completed two open-label, biomarker-driven, Phase 2 studies in MGMT-unmethylated GBM[12]. - The Phase 2/3 studies of REM-001 demonstrated higher tumor response rates compared to alternative treatments for CMBC[85]. - Clinical studies CA008 and CA009 showed a treatment benefit in disease burden with p-values of 0.0017 and 0.0020 respectively[93]. - Average rate of clinical success for study CA013 was 88% (95% CI: 71%-97%) and for CA019 was 83% (95% CI: 45%-86%) with 32 and 18 eligible patients respectively[95]. Drug Mechanism and Efficacy - VAL-083 has been designated as an orphan drug by the FDA for the treatment of gliomas, including GBM, and has received Fast Track Designation for recurrent and newly-diagnosed unmethylated GBM[14][28]. - VAL-083's anti-tumor mechanism is active independent from MGMT status, suggesting its potential as a new standard-of-care in GBM treatment[20][21]. - VAL-083 demonstrated activity against MGMT-unmethylated GBM cells resistant to TMZ, indicating potential as a new treatment option[42]. - VAL-083 has shown superior efficacy and safety compared to standard platinum-based therapy in NSCLC models[49]. - VAL-083's unique mechanism of action allows it to overcome resistance associated with MGMT, suggesting potential to surpass current standard-of-care treatments[45]. - VAL-083 is a novel, validated, DNA-targeting agent for the treatment of drug-resistant solid tumors, including glioblastoma and potentially other solid tumors[6]. Market Potential - The global market for lung cancer treatment is projected to exceed $24 billion by 2033, highlighting significant commercial potential for VAL-083[48]. - VAL-083 is expected to generate over $1.5 billion in sales for glioblastoma multiforme by 2027, and over $22 billion for non-small cell lung cancer by 2027[56]. - The estimated market opportunity for CMBC treatment is approximately $500 million, with a prevalence of CMBC in the U.S. potentially approaching 40,000 cases[79][78]. Strategic Direction and Corporate Structure - The company is evaluating options for strategic direction, which may include raising additional capital or acquiring complementary assets[17]. - The company operates with a "virtual" corporate structure, employing two full-time employees and approximately 15 independent contractors to minimize fixed personnel costs[188]. - The company has undergone several corporate changes, including a merger with Adgero in August 2020, and has rebranded from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc.[186]. Regulatory and Compliance - The FDA granted a Study May Proceed letter for a 15-patient study evaluating REM-001 PDT for CMBC, and the drug has received Fast Track Designation (FTD) from the FDA[69]. - The regulatory approval process requires substantial resources and can be delayed by the need for additional preclinical or clinical data[160]. - The company is subject to ongoing regulatory compliance, including record-keeping and reporting of adverse experiences with drugs post-approval[165]. - The company’s products are subject to rigorous preclinical and clinical testing by the FDA and similar authorities, which can take several years[153]. Intellectual Property - The company has a broad patent portfolio to protect its intellectual property related to VAL-083[15]. - The company has filed patent applications related to VAL-083, including improvements to the manufacturing process and proposed treatment regimens[120]. - The company has filed patent applications for REM-001, including a U.S. patent application for methods of treating cutaneous metastatic cancers, with national phase applications pending in various countries[150]. - The company may seek orphan drug status for new indications, which could provide exclusivity for seven years in the U.S. and Canada, and ten years in the E.U.[139]. Financial Performance - Research and development expenses for the fiscal year ended June 30, 2023, were approximately $9.2 million, down from $15.2 million in 2022, indicating a decrease of about 39.5%[187]. - As of September 14, 2023, the number of shares of common stock outstanding was 1,746,408[190]. Competitive Landscape - The oncology market is highly competitive, with numerous major pharmaceutical and biotechnology companies actively developing products for cancer treatment, which could impact the company's market position[173]. - The competitive landscape includes companies with greater financial resources and expertise, which may pose challenges in recruiting talent and establishing clinical study sites[181]. - Third-party payors are increasingly limiting coverage and reducing reimbursements for medical products, which could adversely affect the company's sales and financial condition[168].

Company Overview - Kintara Therapeutics, Inc. is focused on developing novel cancer therapies, particularly for drug-resistant solid tumors like glioblastoma and ovarian cancer[78]. - The company has two lead candidates: VAL-083, a DNA-targeting agent, and REM-001, a photodynamic therapy for cutaneous metastatic breast cancer, with the latter program paused to conserve cash[79]. Clinical Trials and Studies - The GBM AGILE Study, an international Phase 2/3 clinical study for VAL-083, is ongoing at 39 clinical sites in the U.S., four in Canada, and two in Europe, with over 1,300 patients screened[90]. - Topline results from the GBM AGILE Study are expected by the end of Q4 2023, following the last patient randomization[81]. - VAL-083 has shown anti-tumor activity independent of MGMT expression, which is significant as over 60% of GBM patients have MGMT-unmethylated tumors[84]. - The GBM AGILE Study employs a cost-efficient, adaptive design, with enrollment rates 3 to 4 times greater than traditional studies[90]. - VAL-083 demonstrated activity in cell lines resistant to other chemotherapy types, with no reported cross-resistance in clinical studies[99]. - In clinical studies, approximately 80% of evaluable tumor sites treated with REM-001 Therapy showed a complete response in CMBC patients[101]. Financial Performance - As of March 31, 2023, cash and cash equivalents were $3,045,000, down from $11,780,000 on June 30, 2022[112]. - For the three months ended March 31, 2023, the net loss attributable to common stockholders was $3,266,000, compared to $5,358,000 for the same period in 2022[114]. - Research and development expenses for the nine months ended March 31, 2023, were $7,235,000, a decrease from $11,169,000 in the same period in 2022[115]. - Total assets decreased from $15,948,000 on June 30, 2022, to $6,740,000 on March 31, 2023[112]. - The company has a basic and fully diluted loss per share of $(1.94) for the three months ended March 31, 2023, compared to $(5.45) for the same period in 2022[114]. - Net loss for the three months ended March 31, 2023, was $(3,264), an improvement of $2,092 compared to a net loss of $(5,356) for the same period in 2022[119]. - For the nine months ended March 31, 2023, the company reported a net loss of $(11,314) compared to $(17,215) for the same period in 2022, an improvement of $5,901[127]. Cost Management and Strategic Direction - The company expects to save approximately $3.0 million through calendar 2023 by pausing the REM-001 program to conserve cash[105]. - Kintara is evaluating options for strategic direction, including raising additional capital and potential acquisitions[89]. - The company is pursuing various financing alternatives to fund operations and has paused the REM-001 program to conserve cash for the VAL-083 clinical study[134]. - The company expects to finance future cash needs primarily through public or private equity and debt offerings, and/or strategic collaborations[136]. - If additional funding is not secured, the company may have to delay or reduce the scope of clinical trials or research and development programs[136]. Research and Development Expenses - Research and development expenses decreased to $2,005 for the three months ended March 31, 2023, from $3,474 for the same period in 2022, a reduction of 42%[119]. - General and administrative expenses were $1,297 for the three months ended March 31, 2023, compared to $1,884 for the same period in 2022, a decrease of 31%[119]. - General and administrative expenses for the nine months ended March 31, 2023, were $4,212, compared to $6,055 for the same period in 2022, a reduction of 30%[127]. - Net cash used in operating activities decreased to $(10,357) for the nine months ended March 31, 2023, from $(15,400) for the same period in 2022, a change of 33%[129]. Regulatory Designations - The FDA has granted orphan drug designation for VAL-083 in the treatment of gliomas, including GBM, medulloblastoma, and ovarian cancer[87]. - The FDA granted Fast Track Designation for both VAL-083 in recurrent and newly-diagnosed unmethylated GBM and for REM-001 in CMBC[106]. Compensation and Expense Recognition - The company recognizes compensation costs from stock-based awards over the service period based on fair value measurements[140]. - For the nine months ended March 31, 2023, the company utilized the Black-Scholes model to estimate grant-date fair value for stock option awards[140]. - The company estimates expenses related to clinical trials based on contracts with vendors and adjusts clinical expense recognition as actual results differ from estimates[141]. - There were no material adjustments to prior period estimates of accrued expenses for clinical trials for the nine months ended March 31, 2023, and 2022[141]. - The company does not have any off-balance sheet arrangements[142].

Drug Development and Designation - Kintara Therapeutics received Orphan Drug Designation from the FDA for VAL-083 for the treatment of DIPG, a rare childhood brain cancer [82]. - VAL-083 has been designated as an orphan drug by both the FDA and EMA for the treatment of gliomas, including GBM [87]. - Kintara is evaluating the potential combination of VAL-083 with PARP inhibitors for ovarian cancer, for which it has also received orphan drug designation [86]. - VAL-083 has demonstrated activity against various tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the NCI, leveraging data from over 40 studies [83]. - The GBM AGILE Study employs a cost-efficient, adaptive study design, allowing multiple therapies to be evaluated simultaneously [91]. - Kintara anticipates topline results from the GBM AGILE Study for VAL-083 around the end of Q4 2023 [83]. - The GBM AGILE Study has screened over 1,300 patients, with enrollment rates 3 to 4 times greater than traditional GBM studies [90]. - VAL-083 has shown activity against MGMT-unmethylated GBM cells resistant to TMZ and nitrosoureas, and retains high activity in p53 mutated NSCLC, ovarian cancer, and medulloblastoma [99]. - In clinical studies, REM-001 Therapy achieved a complete response in approximately 80% of evaluable tumor sites in CMBC patients [101]. - VAL-083 and REM-001 have received Fast Track Designations from the FDA for their respective indications [106]. Financial Performance and Strategy - As of December 31, 2022, cash and cash equivalents were $4.874 million, down from $11.780 million on June 30, 2022 [113]. - For the three months ended December 31, 2022, the net loss was $3.454 million, compared to a net loss of $5.893 million for the same period in 2021 [115]. - Research and development expenses for the six months ended December 31, 2022, were $5.230 million, down from $7.695 million in 2021 [116]. - Total assets decreased from $15.948 million on June 30, 2022, to $9.917 million on December 31, 2022 [113]. - Research and development expenses decreased to $2,059 for the three months ended December 31, 2022, from $3,902 for the same period in 2021, a reduction of 47% [121]. - General and administrative expenses were $1,440 for the three months ended December 31, 2022, compared to $1,993 for the same period in 2021, a decrease of 28% [121]. - Net loss for the three months ended December 31, 2022, was $3,454, an improvement of 41% compared to a net loss of $5,893 for the same period in 2021 [121]. - For the six months ended December 31, 2022, research and development expenses decreased to $5,230 from $7,695 in the same period in 2021, a decline of 32% [126]. - General and administrative expenses for the six months ended December 31, 2022, were $2,915, down from $4,171 in the same period in 2021, a decrease of 30% [130]. - Net cash used in operating activities decreased to $8,530 for the six months ended December 31, 2022, from $10,177 for the same period in 2021, a reduction of 16% [132]. - The company reported an accumulated deficit of $144,772 and cash and cash equivalents of $4,874 as of December 31, 2022 [136]. - The company paused the REM-001 program to conserve cash for the development of VAL-083, indicating a strategic shift in resource allocation [124]. - Management is pursuing various financing alternatives to fund operations, including issuing new equity and entering strategic partnerships [137]. - The company has not generated any revenues to date and does not expect to achieve revenues until product candidates are commercialized or partnered [136]. - The company expects to finance future cash needs primarily through public or private equity and debt offerings, and/or strategic collaborations [139]. - If additional funding is not secured, the company may have to delay, reduce, or eliminate clinical trials or research and development programs [139]. Clinical Program Updates - The company paused the REM-001 program to conserve cash, expecting to save approximately $3.0 million through calendar 2023 [82]. - Avastin received full approval in the US, Canada, Australia, and Japan for recurrent GBM, but has a "black-box warning" for severe side effects [97]. - The median survival for GBM patients whose tumors progress after Avastin treatment is less than five months [98]. Accounting and Expense Recognition - The company recognizes compensation costs from stock-based awards over the service period based on fair value measurements [142]. - For the six months ended December 31, 2022, the company utilized the Black-Scholes model to estimate grant-date fair value for stock option awards [142]. - The company estimates expenses for clinical trials based on contracts with vendors and adjusts clinical expense recognition if actual results differ from estimates [143]. - There were no material adjustments to prior period estimates of accrued expenses for clinical trials for the six months ended December 31, 2022, and 2021 [143]. - The company does not have any off-balance sheet arrangements [144].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Registrant's telephone number, including area code) Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

(Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the transition period from to Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | (S ...